Isolation and characterization of protective anti-LPS nanobody against V. cholerae O1 recognizing Inaba and Ogawa serotypes

Applied Microbiology and Biotechnology

Volumn 97, Issue 10, 2013, Pages 4457-4466

  Ebrahimizadeh, Walead ^a   Mousavi Gargari, Seyedlatif ^a   Rajabibazl, Masoumeh ^b   Safaee Ardekani, Leila ^a   Zare, Hamed ^a   Bakherad, Hamid ^a  

^a SHAHED UNIVERSITY   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Lipopolysaccharide; Phage display; VHH; Vibrio cholerae O1

Indexed keywords

CHARACTERIZATION TESTS; HEAVY-CHAIN ANTIBODIES; ISOLATION AND CHARACTERIZATION; LIPOPOLYSACCHARIDES; PHAGE DISPLAY; PROTEOLYTIC RESISTANCE; VHH; VIBRIO CHOLERAE O1;

ANTIBODIES; BACTERIA; DEVELOPING COUNTRIES; HEALTH RISKS;

DISEASES;

BACTERIUM ANTIBODY; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY; NANOBODY; UNCLASSIFIED DRUG; VHH NANOBODY;

ANTIBODY; ANTIGEN; BACTERIUM; CHOLERA; DEVELOPING WORLD; EPIDEMIC; HEALTH RISK; POLYSACCHARIDE; RESEARCH WORK; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIBODY ISOLATION; ANTIBODY PRODUCTION; ARTICLE; CHOLERA; CONTROLLED STUDY; DROMEDARY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE LIBRARY; IN VIVO STUDY; MALE; NONHUMAN; PHAGE DISPLAY; PHAGEMID; PROTEIN DEGRADATION; SEROTYPE; THERMOSTABILITY; VIBRIO CHOLERAE;

BASE SEQUENCE; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; LIPOPOLYSACCHARIDES; NANOSTRUCTURES; POLYMERASE CHAIN REACTION; VIBRIO CHOLERAE;

BACTERIA (MICROORGANISMS); VIBRIO CHOLERAE;

EID: 84877784402     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-012-4518-x     Document Type: Article

References (51)

1. Alam M, Hasan NA, Sadique A, Bhuiyan N, Ahmed KU, Nusrin S, Nair GB, Siddique A, Sack RB, Sack DA (2006) Seasonal cholera caused by Vibrio cholerae serogroups O1 and O139 in the coastal aquatic environment of Bangladesh. Appl Environ Microbiol 72(6):4096-4104 (Pubitemid 43894875)
2. Alam M, Sultana M, Nair GB, Siddique A, Hasan NA, Sack RB, Sack DA, Ahmed K, Sadique A, Watanabe H (2007) Viable but nonculturable Vibrio cholerae O1 in biofilms in the aquatic environment and their role in cholera transmission. Proc Natl Acad Sci 104(45):17801 (Pubitemid 350210915)
3. Ashbolt NJ (2004) Microbial contamination of drinking water and disease outcomes in developing regions. Toxicology 198(1):229-238 (Pubitemid 38609032)
4. Beatty JD, Beatty BG, Vlahos WG (1987) Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. J Immunol Methods 100(1-2):173-179 (Pubitemid 17085455)
5. Behdani M, Zeinali S, Khanahmad H, Karimipour M, Asadzadeh N, Azadmanesh K, Khabiri A, Schoonooghe S, Habibi Anbouhi M, Hassanzadeh-Ghassabeh G (2011) Generation and characterization of a functional nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor. Mol Immunol 50:35-41
6. Bhattacharya K, Kanungo S, Sur D, Sarkar BL, Manna B, Lopez AL, Bhattacharya M, Nandy S, Niyogi SK (2011) Tetracycline-resistant Vibrio cholerae O1, Kolkata, India. Emerg Infect Dis 17(3):568
7. Bhunia R, Ramakrishnan R, Hutin Y, Gupte MD (2009) Cholera outbreak secondary to contaminated pipe water in an urban area, West Bengal, India, 2006. Indian J Gastroenterol 28(2):62-64
8. Bishop AL, Schild S, Patimalla B, Klein B, Camilli A (2010) Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motility. Infect Immun 78(10):4402-4420
9. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72(1-2):248-254
10. Bronze MS, Greenfield RA (eds) (2005) Biodefense: principles and pathogens. Horizon bioscience, Greenfield, 838 pp
11. Brooks GF, Butel JS, Morse SA (2004) Jawetz, Melnick, & Adelberg's medical microbiology. McGraw-Hill, USA, 880 pp
12. Dharmasena MN, Krebs SJ, Taylor RK (2009) Characterization of a novel protective monoclonal antibody that recognizes an epitope common to Vibrio cholerae Ogawa and Inaba serotypes. Microbiology 155(7):2353-2364
13. Dubois M, Gilles KA, Hamilton JK, Rebers P, Smith F (1956) Colorimetric method for determination of sugars and related substances. Anal Chem 28(3):350-356
14. Faruque SM, Sack DA, Sack RB, Colwell RR, Takeda Y, Nair GB (2003) Emergence and evolution of Vibrio cholerae O139. Proc Natl Acad Sci U S A 100(3):1304 (Pubitemid 36183997)
15. Ghassabeh GH, Muyldermans S, Saerens D (2010) Nanobodies, single-domain antigen-binding fragments of camelid heavy-chain antibodies. In: Shire SJ, Gombotz W, Bechtold-Peters K, Andya J (eds) Current trends in monoclonal antibody development and manufacturing. Springer, New York, pp 29-48
16. Goodchild S, Hopkins N, Love T, Patel V, Houghton B, Mayers C (2004) Engineering antibodies to detect biological warfare agents. DTIC Document
17. Haley BJ, Grim CJ, Hasan NA, Taviani E, Chun J, Brettin TS, Bruce DC, Challacombe JF, Detter JC, Han CS (2010) The pre-seventh pandemic Vibrio cholerae BX 330286 El Tor genome: evidence for the environment as a genome reservoir. Environ Microbiol Rep 2(1):208-216
18. Harmsen M, De Haard H (2007) Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol 77(1):13-22 (Pubitemid 47573319)
19. Harris AM, Bhuiyan MS, Chowdhury F, Khan AI, Hossain A, Kendall EA, Rahman A, LaRocque RC, Wrammert J, Ryan ET (2009) Antigen-specific memory B-cell responses to Vibrio cholerae O1 infection in Bangladesh. Infect Immun 77(9):3850-3856
20. Huang L, Muyldermans S, Saerens D (2010) Nanobodies: proficient tools in diagnostics. Expert Rev Mol Diagn 10(6):777-785
21. Igbinosa EO, Okoh AI (2008) Emerging Vibrio species: an unending threat to public health in developing countries. Res Microbiol 159(7):495-506
22. Igbinosa EO, Okoh AI (2009) Toxigenic Vibrio cholerae strains and their associated malaises. Afr J Microbiol Res 3(5):200-211
23. Kolkman JA, Law DA (2010) Nanobodies - from llamas to therapeutic proteins. Drug Discov Today: Technol 7(2):e139-e146
24. Krickeberg K, Pham V, Pham T (2012) Diarrhoea and Cholera. In: Epidemiology. Statistics for Biology and Health. Springer, New York, pp 47-52. doi: 10.1007/978-1-4614-1205-2-6
25. Laeremans T, Van Bergen PPMP (2010) Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses thereof. EP Patent 1:687,338
26. Liu JL, Anderson GP, Delehanty JB, Baumann R, Hayhurst A, Goldman ER (2007) Selection of cholera toxin specific IgNAR single-domain antibodies from a naïve shark library. Mol Immunol 44(7):1775-1783 (Pubitemid 44803164)
27. Malekshahi ZV, Gargari SLM, Rasooli I, Zadeh WE (2011) Treatment of Helicobacter pylori infection in mice with oral administration of egg yolk-driven anti-UreC immunoglobulin. Microb Pathog 51:366-372
28. Mandal S (2011) Cholera epidemic in and around Kolkata, India: endemicity and management. Oman Med J 26(4):288
29. Mishra M, Mohammed F, Akulwar S, Katkar V, Tankhiwale N, Powar R (2004) Re-emergence of El Tor Vibrio in outbreak of cholera in and around Nagpur. Indian J Med Res 120:478-480 (Pubitemid 40044919)
30. Murad F, Alam K, Mazumdar R, Islam S, Nipa M, Iqbal A, Bhuiyan H (2010) Anti-bacterial activity of the extract of Terminalia arjuna against multi antibiotic resistant Vibrio cholerae. J Sci Res 3(1):129
31. Musekiwa A, Volmink J (2011) Oral rehydration salt solution for treating cholera:≤ 270 mOsm/L solutions vs ≥310 mOsm/L solutions. Cochrane Database Syst Rev (12):CD003754
32. Muyldermans S, Baral T, Retamozzo VC, De Baetselier P, De Genst E, Kinne J, Leonhardt H, Magez S, Nguyen V, Revets H (2009) Camelid immunoglobulins and nanobody technology. Vet Immunol Immunopathol 128(1-3):178-183
33. Mwansa J, Mwaba J, Lukwesa C, Bhuiyan N, Ansaruzzaman M, Ramamurthy T, Alam M, Balakrish Nair G (2007) Multiply antibiotic-resistant Vibrio cholerae O1 biotype El Tor strains emerge during cholera outbreaks in Zambia. Epidemiol Infect 135(5):847-853 (Pubitemid 47161670)
34. Nakano T, Matsui M, Inoue I, Awata T, Katayama S, Murakoshi T (2011) Free immunoglobulin light chain: its biology and implications in diseases. Clin Chim Acta 412:843-849
35. Nguyen VK, Muyldermans S, Hamers R (1998) The specific variable domain of camel heavy-chain antibodies is encoded in the germline. J Mol Biol 275(3):413-418 (Pubitemid 28055061)
36. Ogunbanjo PGA, Durrheim DN (2011) Cholera - are we containing the crisis? SA Fam Prac 23(2):2078-6204
37. Qadri F, Svennerholm AM, Faruque A, Sack RB (2005) Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention. Clin Microbiol Rev 18(3):465-483 (Pubitemid 40995112)
38. Roovers RC, van der Linden E, Zijlema H, de Bruïne A, Arends JW, Hoogenboom HR (2001) Evidence for a bias toward intracellular antigens in the local humoral anti-tumor immune response of a colorectal cancer patient revealed by phage display. Int J Cancer 93(6):832-840 (Pubitemid 32756753)
39. Saerens D, Huang L, Bonroy K, Muyldermans S (2008) Antibody fragments as probe in biosensor development. Sensors 8(8):4669-4686
40. Safa A, Bhuiyan NA, Alam M, Sack DA, Nair GB (2005) Genomic relatedness of the new Matlab variants of Vibrio cholerae O1 to the classical and El Tor biotypes as determined by pulsed-field gel electrophoresis. J Clin Microbiol 43(3):1401-1404 (Pubitemid 40364971)
41. Sánchez J, Holmgren J (2011) Cholera toxin - a foe & a friend. Indian J Med Res 133(2):153
42. Schägger H (2006) Tricine-SDS-PAGE. Nat Protoc 1(1):16-22
43. Shale M, Seow C, Coffin C, Kaplan G, Panaccione R, Ghosh S (2010) Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther 31(1):20-34
44. Sharma D, Malik A (2012) Incidence and prevalence of antimicrobial resistant Vibrio cholerae from dairy farms. Afr J Microbiol Res 6(25):5331-5334
45. Shrestha B, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA, Kim T, O'Brien KM, Nelson CA, Johnson S, Fremont DH (2010) The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog 6(4):e1000823
46. Siddique A, Nair G, Alam M, Sack D, Huq A, Nizam A, Longini I, Qadri F, Faruque S, Colwell R (2010) El Tor cholera with severe disease: a new threat to Asia and beyond. Epidemiol Infect 138(3):347
47. Svennerholm A, Holmgren J (1976) Synergistic protective effect in rabbits of immunization with Vibrio cholerae lipopolysaccharide and toxin/toxoid. Infect Immun 13(3):735-740
48. Taneja N, Kaur J, Sharma K, Singh M, Kalra J, Sharma N, Sharma M (2003) A recent outbreak of cholera due to Vibrio cholerae O1 Ogawa in & around Chandigarh, North India. Indian J Med Res 117:243-246 (Pubitemid 37461224)
49. Thompson CC, Freitas FS, Marin MA, Fonseca EL, Okeke IN, Vicente ACP (2011) Vibrio cholerae O1 lineages driving cholera outbreaks during seventh cholera pandemic in Ghana. Infect Genet Evol 11:1951-1956
50. Weil AA, Arifuzzaman M, Bhuiyan TR, LaRocque RC, Harris AM, Kendall EA, Hossain A, Tarique AA, Sheikh A, Chowdhury F (2009) Memory T-cell responses to Vibrio cholerae O1 infection. Infect Immun 77(11):5090-5096
51. Wesolowski J, Alzogaray V, Reyelt J, Unger M, Juarez K, Urrutia M, Cauerhff A, Danquah W, Rissiek B, Scheuplein F (2009) Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol 198(3):157-174